127 related articles for article (PubMed ID: 9271323)
21. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.
Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G
Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040
[TBL] [Abstract][Full Text] [Related]
22. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
23. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
24. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
Franzke A; Buer J; Probst-Kepper M; Lindig C; Framzle M; Schrader AJ; Ganser A; Atzpodien J
Cancer Biother Radiopharm; 2001 Oct; 16(5):401-9. PubMed ID: 11776757
[TBL] [Abstract][Full Text] [Related]
25. Serum neopterin as a parameter for monitoring the course of renal cell carcinoma during interferon-gamma therapy.
Höbarth K; Szabo N; Hallas A; Aulitzky W; Marberger M
Clin Immunol Immunopathol; 1994 Mar; 70(3):241-4. PubMed ID: 8313661
[TBL] [Abstract][Full Text] [Related]
26. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
[TBL] [Abstract][Full Text] [Related]
27. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
Pantuck AJ; Belldegrun AS; Figlin RA
N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
[No Abstract] [Full Text] [Related]
28. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
29. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma.
Ljungberg B; Grankvist K; Rasmuson T
Eur J Cancer; 1997 Oct; 33(11):1794-8. PubMed ID: 9470835
[TBL] [Abstract][Full Text] [Related]
30. Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma.
Atzpodien J; Wandert T; Reitz M
Crit Rev Oncol Hematol; 2005 Sep; 55(3):193-9. PubMed ID: 16115777
[TBL] [Abstract][Full Text] [Related]
31. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
[TBL] [Abstract][Full Text] [Related]
32. Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2.
Miles D; Thomsen L; Balkwill F; Thavasu P; Moncada S
Eur J Clin Invest; 1994 Apr; 24(4):287-90. PubMed ID: 8050458
[TBL] [Abstract][Full Text] [Related]
33. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors.
Guida M; Casamassima A; Monticelli G; Quaranta M; Colucci G
J Transl Med; 2007 Oct; 5():51. PubMed ID: 17953739
[TBL] [Abstract][Full Text] [Related]
34. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
Br J Cancer; 1998 Apr; 77(8):1311-7. PubMed ID: 9579838
[TBL] [Abstract][Full Text] [Related]
35. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Novara G
Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
[No Abstract] [Full Text] [Related]
36. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract][Full Text] [Related]
37. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy.
Kedar I; Mermershtain W; Ivgi H
Int J Cancer; 2004 Jun; 110(2):260-5. PubMed ID: 15069691
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
Garcia JA; Mekhail T; Elson P; Wood L; Bukowski RM; Dreicer R; Rini BI
BJU Int; 2012 Jan; 109(1):63-9. PubMed ID: 21244601
[TBL] [Abstract][Full Text] [Related]
39. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
[TBL] [Abstract][Full Text] [Related]
40. Expression of the interleukin 6 receptor in primary renal cell carcinoma.
Costes V; Liautard J; Picot MC; Robert M; Lequeux N; Brochier J; Baldet P; Rossi JF
J Clin Pathol; 1997 Oct; 50(10):835-40. PubMed ID: 9462266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]